Deborah Donnell

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence
    DEBORAH J DONNELL
    Department of Global Health, University of Washington, Seattle, USA
    AIDS Behav 17:632-9. 2013
  2. ncbi HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043)
    Estelle Piwowar-Manning
    Dept of Pathology, Johns Hopkins Univ, School of Medicine, Baltimore, MD, USA
    BMC Infect Dis 11:251. 2011
  3. ncbi Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial
    Deborah Donnell
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Ctr, Seattle, WA 98109, USA
    AIDS Behav 14:1182-9. 2010
  4. ncbi Challenges in the design of HIV prevention trials in the United States
    Deborah Donnell
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 55:S136-40. 2010
  5. ncbi Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
  6. ncbi Quantifying ongoing HIV-1 exposure in HIV-1-serodiscordant couples to identify individuals with potential host resistance to HIV-1
    Romel D Mackelprang
    Department of Global Health, University of Washington, WA, USA
    J Infect Dis 206:1299-308. 2012
  7. ncbi Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships
    Patrick Ndase
    Department of Global Health, University of Washington, Seattle, 98104, USA
    J Acquir Immune Defic Syndr 59:65-71. 2012
  8. ncbi Hormonal contraceptive use and risk of HIV-1 disease progression
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, Washington 98104, USA
    AIDS 27:261-7. 2013
  9. ncbi Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
  10. ncbi Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e25828. 2011

Collaborators

Detail Information

Publications16

  1. ncbi Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence
    DEBORAH J DONNELL
    Department of Global Health, University of Washington, Seattle, USA
    AIDS Behav 17:632-9. 2013
    ..e., fewer pills returned than expected) and when pill counts were missing because bottles were not returned, plasma HIV-1 RNA and GUD effects were diminished, likely indicating periods of non-adherence...
  2. ncbi HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043)
    Estelle Piwowar-Manning
    Dept of Pathology, Johns Hopkins Univ, School of Medicine, Baltimore, MD, USA
    BMC Infect Dis 11:251. 2011
    ..We evaluated the accuracy of in-country HIV rapid testing and determined HIV prevalence in the Project Accept pilot study...
  3. ncbi Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial
    Deborah Donnell
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Ctr, Seattle, WA 98109, USA
    AIDS Behav 14:1182-9. 2010
    ....
  4. ncbi Challenges in the design of HIV prevention trials in the United States
    Deborah Donnell
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 55:S136-40. 2010
    ..However, for interventions where efficacy is already established, conducting trials that test different implementation strategies in these populations could provide definitive evidence about how to achieve high levels of coverage...
  5. ncbi Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
    ..Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations...
  6. ncbi Quantifying ongoing HIV-1 exposure in HIV-1-serodiscordant couples to identify individuals with potential host resistance to HIV-1
    Romel D Mackelprang
    Department of Global Health, University of Washington, WA, USA
    J Infect Dis 206:1299-308. 2012
    ..We developed a novel approach for quantifying HIV-1 exposure to identify individuals remaining HIV-1 uninfected despite persistent high exposure...
  7. ncbi Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships
    Patrick Ndase
    Department of Global Health, University of Washington, Seattle, 98104, USA
    J Acquir Immune Defic Syndr 59:65-71. 2012
    ..As African countries scale-up couples HIV testing, little is known about sexual behaviors and HIV risk for HIV-uninfected partners in known HIV-serodiscordant relationships...
  8. ncbi Hormonal contraceptive use and risk of HIV-1 disease progression
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, Washington 98104, USA
    AIDS 27:261-7. 2013
    ..For HIV-1-infected women, hormonal contraception prevents unintended pregnancy, excess maternal morbidity, and vertical HIV-1 transmission. Hormonal contraceptives are widely used but their effects on HIV-1 disease progression are unclear...
  9. ncbi Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
    ..Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners...
  10. ncbi Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e25828. 2011
    ..We describe the trial design and characteristics of the study cohort...
  11. ncbi Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure
    Jairam R Lingappa
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e28632. 2011
    ..To minimize misclassification of HIV-1 risk, we quantified HIV-1 exposure, using data including plasma HIV-1 concentrations, gender, and condom use...
  12. ncbi Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Lancet Infect Dis 12:19-26. 2012
    ..We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners...
  13. ncbi Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk
    Jairam R Lingappa
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 5:e12598. 2010
    ....
  14. ncbi Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98195, USA
    Sci Transl Med 3:77ra29. 2011
    ..These data suggest that HIV-1 RNA in genital secretions could be used as a marker of HIV-1 sexual transmission risk...
  15. ncbi Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples
    Ying Qing Chen
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Contemp Clin Trials 33:1280-6. 2012
    ..Nevertheless, the durability of its long-term effectiveness is yet to be assessed. The HPTN 052 Study is still ongoing and will not complete till 2015...
  16. ncbi Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples
    Jared M Baeten
    University of Washington, WA, USA
    AIDS 24:737-44. 2010
    ....